Assessing the number of nuclear foci of RAD51, FANCD2 and γH2AX may help to establish DDR cellular competence, before, during and after treatment with IR and PARP inhibitors, to predict tumor sensitivity or acquired resistance to treatments. The gene discussed is PARP1; the disease is neoplasm.